Gsk (GLAXF) Non-Current Deferred Tax Liability (2016 - 2025)
Historic Non-Current Deferred Tax Liability for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to -$526.1 million.
- Gsk's Non-Current Deferred Tax Liability fell 3773.21% to -$526.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$526.1 million, marking a year-over-year decrease of 3773.21%. This contributed to the annual value of -$488.3 million for FY2024, which is 22623.18% down from last year.
- Per Gsk's latest filing, its Non-Current Deferred Tax Liability stood at -$526.1 million for Q3 2025, which was down 3773.21% from -$512.3 million recorded in Q2 2025.
- In the past 5 years, Gsk's Non-Current Deferred Tax Liability registered a high of $4.8 billion during Q4 2021, and its lowest value of -$5.1 billion during Q3 2021.
- Its 5-year average for Non-Current Deferred Tax Liability is -$1.0 billion, with a median of -$490.3 million in 2024.
- As far as peak fluctuations go, Gsk's Non-Current Deferred Tax Liability skyrocketed by 9625.75% in 2022, and later crashed by 23345.18% in 2023.
- Quarter analysis of 5 years shows Gsk's Non-Current Deferred Tax Liability stood at $4.8 billion in 2021, then tumbled by 92.93% to $339.0 million in 2022, then rose by 13.87% to $386.0 million in 2023, then crashed by 227.02% to -$490.3 million in 2024, then decreased by 7.31% to -$526.1 million in 2025.
- Its Non-Current Deferred Tax Liability stands at -$526.1 million for Q3 2025, versus -$512.3 million for Q2 2025 and -$508.8 million for Q1 2025.